Bengaluru-based biopharmaceuticals major Biocon Limited announced few significant aspirations and already achieved milestones. Biocon Group Chairperson Kiran Mazumdar-Shaw announced that the company aims to become the global leader in the insulin market within the next five years. Amazon Brand - Myx Women's Schiffli Embroidery Ethnic Dress | Fit and Flare | Knee Length (Available in Plus Sizes)

The group’s "one in five" strategy is designed to fill the vacuum left by global pharmaceutical giants who are shifting their focus away from traditional insulin toward high-demand GLP-1 weight-loss and diabetes drugs. It aims to capture 20% of the world’s insulin market by 2031, catering 1 in 5 insulin-dependent patients globally.

Approximately 537 million adults were living with diabetes in 2021, the age group from 20 to 80. Biocon foresees the number to rise to 643 million by 2030, and 783 million by 2045.

Biocon has emerged as the third-largest supplier by biologic volume of both rh-Insulin and Insulin Glargine worldwide. Deadline Diplomacy: Iran Proposes 10-Point Plan to Avert Escalation

Biocon has a substantial presence in the US market and currently one in five insulin-dependent patients in the US use only Biocon’s insulin and the company aims to capture similar market size world over, including India. Shreehas Tambe, CEO and MD of Biocon said, the company aims at tapping at least 20% of the global market. Yet another blow to Congress, will they exist in Indian political arena for more than a decade?

Major companies are turning towards vials and GLP-1s, leaving a massive gap in the production of pens and cartridges. Biocon is currently the only company focusing on these formats.